{
    "organizations": [],
    "uuid": "1f7645c62318b097f2b855fd719f51cd9c8b5347",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-indias-bal-pharma-dec-qtr-profit-r/brief-indias-bal-pharma-dec-qtr-profit-rises-idUSFWN1Q411K",
    "ord_in_thread": 0,
    "title": "BRIEF-India's Bal Pharma Dec-Qtr Profit Rises",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - India’s Bal Pharma Ltd:\n* DEC QUARTER NET PROFIT 17.4 MILLION RUPEES VERSUS PROFIT OF 15.9 MILLION RUPEES YEAR AGO\n* DEC QUARTER REVENUE FROM OPERATIONS 519.4 MILLION RUPEES VERSUS 584.4 MILLION RUPEES YEAR AGO\n* SAYS ACCEPTED RESIGNATION OF SANJAY KUMAR AGARWAL FROM POST OF CFO\n* APPROVED SIGNING OF JOINT VENTURE AGREEMENT WITH AKAAL PHARMA FOR DEVELOPMENT AND MARKETING OF VETERINARY MEDICINES​ Source text - bit.ly/2Eul5Qb Further company coverage:\n ",
    "published": "2018-02-14T20:32:00.000+02:00",
    "crawled": "2018-02-15T20:43:58.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "india",
        "bal",
        "pharma",
        "ltd",
        "dec",
        "quarter",
        "net",
        "profit",
        "million",
        "rupee",
        "versus",
        "profit",
        "million",
        "rupee",
        "year",
        "ago",
        "dec",
        "quarter",
        "revenue",
        "operation",
        "million",
        "rupee",
        "versus",
        "million",
        "rupee",
        "year",
        "ago",
        "say",
        "accepted",
        "resignation",
        "sanjay",
        "kumar",
        "agarwal",
        "post",
        "cfo",
        "approved",
        "signing",
        "joint",
        "venture",
        "agreement",
        "akaal",
        "pharma",
        "development",
        "marketing",
        "veterinary",
        "source",
        "text",
        "company",
        "coverage"
    ]
}